With a number of gene therapies advancing into later-stage trials the field has begun to attract significant amounts of both private and public capital investments once again. According to BioWorld Snapshots, more than $200 million in venture capital has been invested into companies developing gene therapies this year alone. Read More
"Sell in May and go away" is an oft-quoted investment strategy for equities but it seems that biotech investors are bucking that trend big time. The BioWorld Blue Chip Biotech Index has jumped 5.2 percent in value for the month by the close of the markets last Thursday, thanks to stellar performances from many of the leading biotech companies in the group. Read More
